BamSEC and AlphaSense Join Forces
Learn More

Mineralys Therapeutics Inc. – Material Contracts

NASDAQ: MLYS    
Share price (11/10/26): $15.52    
Market cap (11/10/26): $1.374 billion
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.2
from 10-Q 12 pages August 5, 2026 via Email James J. Ferguson III [***] [***] Re: Employment Offer Letter Dear Terry: Mineralys Therapeutics, Inc. (The “Company”) Is Pleased to Offer You a Position on the Terms Set Forth in This Letter (This “Agreement”). •employment Start Date. We Expect That Your Start Date Will Be on or Prior to August 10, 2026 (The “Start Date”). This Offer, if Not Accepted, Will Expire at the Close of Business on August 7, 2026
12/34/56
EX-10.5
from 10-Q 143 pages [***] Certain Information in This Document Has Been Excluded Pursuant to Regulation S-K, Item 601(b)(10). Such Excluded Information Is Not Material and Is Treated by the Registrant as Private or Confidential
12/34/56
EX-10.4
from 10-Q 11 pages [***] Certain Information in This Document Has Been Excluded Pursuant to Regulation S-K, Item 601(b)(10). Such Excluded Information Is Not Material and Is Treated by the Registrant as Private or Confidential. Fourth Amendment to License Agreement
12/34/56
EX-10.3
from 10-Q 4 pages [***] Certain Information in This Document Has Been Excluded Pursuant to Regulation S-K, Item 601(b)(10). Such Excluded Information Is Not Material and Is Treated by the Registrant as Private or Confidential. Confidential Amendment No.3 to License Agreement This Amendment No.3 to License Agreement (This “Amendment No.3”), Recitals
12/34/56
EX-10.2
from 10-Q 3 pages [***] Certain Information in This Document Has Been Excluded Pursuant to Regulation S-K, Item 601(b)(10). Such Excluded Information Is Not Material and Is Treated by the Registrant as Private or Confidential. Confidential Amendment No.2 to License Agreement This Amendment No.2 to License Agreement (This “Amendment No.2”), Recitals
12/34/56
EX-10.1
from 10-Q 3 pages [***] Certain Information in This Document Has Been Excluded Pursuant to Regulation S-K, Item 601(b)(10). Such Excluded Information Is Not Material and Is Treated by the Registrant as Private or Confidential. Amendment No. 1 to License Agreement
12/34/56
EX-10.1
from 8-K 2 pages August 5, 2026 David Rodman, M.D. Re: Amendment to Employment Letter Agreement Dear Dr. Rodman
12/34/56
EX-10.1
from 10-Q 3 pages Mineralys Therapeutics, Inc. Non-Employee Director Compensation Program as Amended and Restated Effective February 19, 2026
12/34/56
EX-10.9
from 10-K 10 pages April 3, 2025 via Email Eric Warren
12/34/56
EX-10.5
from 10-K 3 pages Mineralys Therapeutics, Inc. Non-Employee Director Compensation Program as Amended and Restated Effective February 19, 2026
12/34/56
EX-10.2
from 10-K 61 pages Eligibility
12/34/56
EX-10.12
from 10-K 34 pages Eligibility
12/34/56
EX-10.1
from 8-K 32 pages Mineralys Therapeutics, Inc. Securities Purchase Agreement
12/34/56
EX-10.7
from S-1/A 11 pages February 1, 2023 Adam Levy Re: Amended and Restated Employment Letter Dear Adam
12/34/56
EX-10.6
from S-1/A 11 pages February 1, 2023 David Rodman, M.D. Re: Amended and Restated Employment Letter Dear Dr. Rodman
12/34/56
EX-10.5
from S-1/A 11 pages February 1, 2023 Jon Congleton Re: Amended and Restated Employment Letter Dear Jon
12/34/56
EX-10.4
from S-1/A 3 pages Mineralys Therapeutics, Inc. Non-Employee Director Compensation Program
12/34/56
EX-10.3
from S-1/A 15 pages Mineralys Therapeutics, Inc. 2023 Employee Stock Purchase Plan
12/34/56
EX-10.2
from S-1/A 37 pages Eligibility
12/34/56
EX-10.1
from S-1/A 19 pages Mineralys Therapeutics, Inc. 2020 Equity Incentive Plan
12/34/56